- Home
- BCAB vs LRE Comparison
BCAB vs LRE Comparison
Compare BCAB & LRE Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
- Machine Learning Prediction
- ML Decision
- BCAB
- LRE
- Stock Information
- Founded
- BCAB 2007
- LRE 2001
- Country
- BCAB United States
- LRE Japan
- Employees
- BCAB N/A
- LRE N/A
- Industry
- BCAB Medicinal Chemicals and Botanical Products
- LRE
- Sector
- BCAB Health Care
- LRE
- Exchange
- BCAB Nasdaq
- LRE Nasdaq
- Market Cap
- BCAB 22.3M
- LRE 17.6M
- IPO Year
- BCAB 2020
- LRE 2023
- Fundamental
- Price
- BCAB $0.38
- LRE $1.79
- Analyst Decision
- BCAB Buy
- LRE
- Analyst Count
- BCAB 2
- LRE 0
- Target Price
- BCAB $1.00
- LRE N/A
- AVG Volume (30 Days)
- BCAB 491.4K
- LRE 15.0K
- Earning Date
- BCAB 08-07-2025
- LRE 01-01-0001
- Dividend Yield
- BCAB N/A
- LRE N/A
- EPS Growth
- BCAB N/A
- LRE N/A
- EPS
- BCAB N/A
- LRE N/A
- Revenue
- BCAB $11,000,000.00
- LRE $110,330,328.00
- Revenue This Year
- BCAB N/A
- LRE N/A
- Revenue Next Year
- BCAB N/A
- LRE N/A
- P/E Ratio
- BCAB N/A
- LRE $6.14
- Revenue Growth
- BCAB N/A
- LRE 8.82
- 52 Week Low
- BCAB $0.24
- LRE $1.10
- 52 Week High
- BCAB $2.53
- LRE $2.49
- Technical
- Relative Strength Index (RSI)
- BCAB 42.25
- LRE 57.64
- Support Level
- BCAB $0.36
- LRE $1.71
- Resistance Level
- BCAB $0.43
- LRE $2.11
- Average True Range (ATR)
- BCAB 0.04
- LRE 0.12
- MACD
- BCAB -0.00
- LRE -0.01
- Stochastic Oscillator
- BCAB 16.10
- LRE 34.69
About BCAB BioAtla Inc.
BioAtla Inc is a clinical-stage biopharmaceutical company. The company is engaged in the development of a novel class of specific and selective antibody-based therapeutics for the treatment of solid tumor cancer. Its pipeline products comprise mecbotamab vedotin (BA3011), ozuriftamab vedotin (BA3021), and evalstotug (BA3071), and its Phase 1 clinical trial of BA3182 (CAB-EpCAM x CAB-CD3) and Bispecific antibody programs.
About LRE Lead Real Estate Co. Ltd
Lead Real Estate Co Ltd operates as a developer of luxury residential properties, including single-family homes and condominiums, across Tokyo, Kanagawa prefecture, and Sapporo. The company also operates hotels in Tokyo and leases apartment building units to individual customers in Japan and Dallas, Texas. Predominantly, its revenue is generated from developing and selling single-family homes and condominiums. The company's sole operating segment is real estate sales. Geographically, it derives revenue from Japan.